Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES PLIMPTON

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1891777835
CMS profile
267685
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,037.66

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,296.55 6
Food and Beverage $741.11 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,037.66 8

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES PLIMPTON

NPI 1891777835 · CMS profile ID 267685

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $3,037.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $578.4611/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673851687 CMS
PFIZER INC. $389.3511/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852271 CMS
PFIZER INC. $314.1911/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852273 CMS
PFIZER INC. $86.4011/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852275 CMS
PFIZER INC. $467.2207/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030491 CMS
PFIZER INC. $130.4307/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030499 CMS
PFIZER INC. $654.7107/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030505 CMS
PFIZER INC. $416.9007/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030511 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,037.66 8
PY2020 $4,550.00 1
PY2024 $164.80 3
PY2025 $63.56 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $280,140.77 30
PY2024 Principal investigator $631,342.46 58
PY2023 Principal investigator $604,319.86 129
PY2022 Principal investigator $1,688,412.68 133
PY2021 Principal investigator $3,601,852.60 159
PY2020 Principal investigator $853,852.30 65
PY2019 Principal investigator $195,210.58 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

133 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $34,362.90 12/30/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949758787
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,250.00 12/27/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216483
Principal investigator 1 PFIZER INC. $219.38 12/24/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949757569
Principal investigator 1 ModernaTX, Inc. $1,759.88 12/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963496669
Principal investigator 1 Janssen Pharmaceuticals, Inc $729.00 12/16/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216487
Principal investigator 1 PFIZER INC. $14,756.86 12/16/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949758095
Principal investigator 1 ModernaTX, Inc. $395.20 12/14/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963496655
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/07/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982467
Principal investigator 1 PFIZER INC. $22,242.00 12/07/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949758083
Principal investigator 1 PFIZER INC. $35,976.60 12/06/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757917
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,989.00 12/05/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216491
Principal investigator 1 ModernaTX, Inc. $37.04 12/01/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963496627
Principal investigator 1 ModernaTX, Inc. $4,025.75 12/01/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963496693
Principal investigator 1 ModernaTX, Inc. $3,992.95 11/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493649
Principal investigator 1 ModernaTX, Inc. $3,760.58 11/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 963493659
Principal investigator 1 PFIZER INC. $1,974.38 11/24/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949757405
Principal investigator 1 PFIZER INC. $4,750.00 11/24/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949758035
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 11/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982425
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 11/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982455
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 11/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982553
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 11/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982631
Principal investigator 1 ModernaTX, Inc. $11,543.68 11/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493643
Principal investigator 1 ModernaTX, Inc. $7,500.00 11/18/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963493677
Principal investigator 1 GlaxoSmithKline, LLC. $3,706.56 11/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982539
Principal investigator 1 ModernaTX, Inc. $12,158.58 11/09/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493633
Principal investigator 1 ModernaTX, Inc. $9,737.98 11/09/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493639
Principal investigator 1 PFIZER INC. $8,500.00 11/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949758241
Principal investigator 1 ModernaTX, Inc. $13,286.00 11/04/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493653
Principal investigator 1 ModernaTX, Inc. $1,796.93 11/02/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493629
Principal investigator 1 ModernaTX, Inc. $5,890.95 11/02/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963493673
Principal investigator 1 PFIZER INC. $6,969.60 10/28/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949758861
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,509.00 10/26/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216499
Principal investigator 1 ModernaTX, Inc. $21,571.55 10/26/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493599
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 10/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982509
Principal investigator 1 PFIZER INC. $42,848.80 10/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949758253
Principal investigator 1 GlaxoSmithKline, LLC. $18,350.00 10/21/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 943982661
Principal investigator 1 PFIZER INC. $14,000.00 10/15/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757713
Principal investigator 1 ModernaTX, Inc. $2,418.65 10/14/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493595
Principal investigator 1 ModernaTX, Inc. $3,633.99 10/14/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 963493605
Principal investigator 1 GlaxoSmithKline, LLC. $2,031.48 10/12/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982437
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,304.00 10/10/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216495
Principal investigator 1 ModernaTX, Inc. $8,271.58 10/07/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493589
Principal investigator 1 ModernaTX, Inc. $3,267.55 10/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963493585
Principal investigator 1 ModernaTX, Inc. $6,551.68 10/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963493623
Principal investigator 1 PFIZER INC. $11,536.80 09/30/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757853
Principal investigator 1 GlaxoSmithKline, LLC. $1,668.15 09/27/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982649
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,629.00 09/26/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216393
Principal investigator 1 ModernaTX, Inc. $109,322.20 09/23/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521831
Principal investigator 1 PFIZER INC. $14,500.00 09/23/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949758409
Principal investigator 1 PFIZER INC. $40,830.90 09/22/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757589
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982667
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982673
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982679
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982685
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982691
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/20/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE IIIB, OPEN LABEL, NON-RANDOMIZED, CONTROLLED, MULTI COUNTRY ST No dispute reported 06/30/2026 943982697
Principal investigator 1 ModernaTX, Inc. $1,536.34 09/19/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521537
Principal investigator 1 ModernaTX, Inc. $1,900.00 09/19/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521539
Principal investigator 1 GlaxoSmithKline, LLC. $12,573.00 09/14/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982533
Principal investigator 1 ModernaTX, Inc. $910.00 09/09/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521533
Principal investigator 1 ModernaTX, Inc. $5,137.60 08/29/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963521907
Principal investigator 1 ModernaTX, Inc. $13,703.30 08/26/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521543
Principal investigator 1 PFIZER INC. $26,043.60 08/26/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757441
Principal investigator 1 GlaxoSmithKline, LLC. $2,053.26 08/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982577
Principal investigator 1 ModernaTX, Inc. $34,741.53 08/12/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521825
Principal investigator 1 GlaxoSmithKline, LLC. $15,000.00 08/01/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982583
Principal investigator 1 PFIZER INC. $6,164.40 07/29/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949746375
Principal investigator 1 Janssen Pharmaceuticals, Inc $395.00 07/22/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216389
Principal investigator 1 PFIZER INC. $689.04 07/22/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949757793
Principal investigator 1 Janssen Pharmaceuticals, Inc $10,704.00 07/20/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216397
Principal investigator 1 ModernaTX, Inc. $333.45 07/15/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521833
Principal investigator 1 PFIZER INC. $32,109.00 07/14/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757887
Principal investigator 1 ModernaTX, Inc. $6,638.13 07/13/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963521911
Principal investigator 1 PFIZER INC. $9,999.00 06/24/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757997
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,545.00 06/20/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216385
Principal investigator 1 ModernaTX, Inc. $64,448.48 06/08/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521829
Principal investigator 1 PFIZER INC. $23,116.50 06/07/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757879
Principal investigator 1 ModernaTX, Inc. $1,259.70 06/03/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521535
Principal investigator 1 ModernaTX, Inc. $29,497.73 06/03/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 963521919
Principal investigator 1 GlaxoSmithKline, LLC. $1,158.30 05/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982595
Principal investigator 1 PFIZER INC. $118,679.55 05/21/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949755195
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,946.00 05/20/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216381
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982401
Principal investigator 1 GlaxoSmithKline, LLC. $4,993.56 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982559
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 05/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982609
Principal investigator 1 Janssen Pharmaceuticals, Inc $295.00 05/09/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216377
Principal investigator 1 ModernaTX, Inc. $30,566.25 05/04/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521821
Principal investigator 1 PFIZER INC. $894.96 05/03/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949755201
Principal investigator 1 GlaxoSmithKline, LLC. $1,814.67 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982443
Principal investigator 1 GlaxoSmithKline, LLC. $2,619.54 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982461
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982479
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 04/25/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982497
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,053.00 04/25/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216373
Principal investigator 1 PFIZER INC. $609.84 04/19/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949758267
Principal investigator 1 PFIZER INC. $39,378.90 04/14/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757749
Principal investigator 1 ModernaTX, Inc. $10,645.70 04/13/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521541
Principal investigator 1 PFIZER INC. $58,908.96 04/08/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757795
Principal investigator 1 GlaxoSmithKline, LLC. $4,151.07 04/06/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982431
Principal investigator 1 GlaxoSmithKline, LLC. $264.33 04/06/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982625
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,063.00 03/28/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216293
Principal investigator 1 GlaxoSmithKline, LLC. $4,273.83 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982407
Principal investigator 1 GlaxoSmithKline, LLC. $4,067.91 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982503
Principal investigator 1 GlaxoSmithKline, LLC. $1,139.49 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982589
Principal investigator 1 GlaxoSmithKline, LLC. $2,812.59 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982601
Principal investigator 1 GlaxoSmithKline, LLC. $3,005.64 03/23/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982613
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,220.00 03/18/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216291
Principal investigator 1 GlaxoSmithKline, LLC. $772.20 03/16/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982419
Principal investigator 1 GlaxoSmithKline, LLC. $14,119.38 03/16/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982521
Principal investigator 1 GlaxoSmithKline, LLC. $6,673.59 03/16/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982637
Principal investigator 1 PFIZER INC. $6,793.05 03/16/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949758007
Principal investigator 1 GlaxoSmithKline, LLC. $3,404.61 03/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982515
Principal investigator 1 ModernaTX, Inc. $31,758.03 03/04/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521823
Principal investigator 1 PFIZER INC. $116,820.99 03/04/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757989
Principal investigator 1 Janssen Pharmaceuticals, Inc $21,925.00 02/16/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216287
Principal investigator 1 GlaxoSmithKline, LLC. $5,290.56 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982527
Principal investigator 1 GlaxoSmithKline, LLC. $2,266.11 02/09/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982619
Principal investigator 1 PFIZER INC. $860.64 02/05/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 949757913
Principal investigator 1 ModernaTX, Inc. $41,224.30 01/28/2022 Non-covered Recipient Entity
MedPharmics, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963521827
Principal investigator 1 PFIZER INC. $193,678.65 01/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949757429
Principal investigator 1 PFIZER INC. $1,504.80 01/25/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949758171
Principal investigator 1 GlaxoSmithKline, LLC. $2,084.94 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982413
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982449
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982473
Principal investigator 1 GlaxoSmithKline, LLC. $3,578.85 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982485
Principal investigator 1 GlaxoSmithKline, LLC. $5,136.12 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982547
Principal investigator 1 GlaxoSmithKline, LLC. $605.88 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982565
Principal investigator 1 GlaxoSmithKline, LLC. $290.07 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 943982571
Principal investigator 1 GlaxoSmithKline, LLC. $1,268.19 01/24/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982643
Principal investigator 1 Janssen Pharmaceuticals, Inc $28,698.00 01/21/2022 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885216283
Principal investigator 1 Abbott Laboratories $16,956.48 01/11/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
Alinity m HR HPV Specimen Collection Study from Women Undergoing Routine Cervical cancer Screening No dispute reported 06/30/2026 914487859
Principal investigator 1 PFIZER INC. $15,368.10 01/11/2022 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949758617
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.00 01/05/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982491
Principal investigator 1 GlaxoSmithKline, LLC. $2,800.00 01/05/2022 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 943982655